Group items tagged

The Pharmacists' Defence Association (PDA) said it has supported the application of the Royal Pharmaceutical Society (RPS) to rejoin the International Pharmaceutical Federation (FIP), the global body representing the interests of pharmacy. Under FIP rules, if a new application from an additional organisation from the same country applies to join, the existing members in that country are consulted about that decision and are asked for their approval before FIP council members determine if the application is accepted. The PDA joined FIP earlier this year, and RPS, which has decided not to renew FIP membership at the end of last year, has now submitted a fresh application to join. RPS decision to leave, taken after a vote, has invited much criticism. The organisation, a founding member, had attributed high membership fees and associated costs for leaving FIP While the PDA has confirmed that it would not oppose the membership application of the RPS, it has asked FIP to find a suitable method to ascertain a transparent declaration of membership numbers from the RPS in the event of FIP Council deciding to admit RPS.

British pharmaceutical giant GSK said on Saturday (April 15) its oral antibiotic drug to treat uncomplicated urinary tract infections (uUTI) in female adults and adolescents met the main goals in late-stage trials. The drug, gepotidacin, in phase III trials, met its primary goals of being on a par or better than nitrofurantoin, the current standard of care for the treatment of uUTIs, the company said. GSK plans to submit results of the trials to the United States Food and Drug Administration for review later in the second quarter. The drug, if approved, could become the first new type of antibiotic, which is critically important for countering drug-resistant infections, to treat uUTIs in 20 years, the company said. "Gepotidacin, if approved, will offer a much-needed additional oral treatment option for patients at risk of treatment failure associated with resistance or recurrence of uUTI," Chris Corsico, senior vice president of development at GSK, said.

The Royal Pharmaceutical Society (RPS) on Wednesday (14 February) launched consultations on two new pioneer curricula defining the clinical capabilities expected of entry-level advanced pharmacists practising in critical care and mental health. The advanced pharmacist critical care curriculum and the advanced pharmacist mental health curriculum are supplementary to the RPS core advanced curriculum. Interested stakeholders are invited to provide feedback on the content of the curricula, their feasibility in terms of delivery, their relevance to all countries, and how these may impact different social groups. Both consultations will be open until Tuesday 12 March, and members and non-members of RPS can submit their comments via the online form or the word document.

Medipharmacy has been bought out by PI-Gen Pharma Limited, an arm of the independent pharmacy group Enimed, for a total of £7.1 million, after the business entered into administration. In a report published on Companies House on January 30, administrators at FRP confirmed that the transaction was completed on 18 January, with PI-Gen beating five other bidders to acquire the insolvent NHS pharmacy chain. The report added that PI-Gen submitted a cash offer of non-refundable £500k for Medipharmacy's goodwill, £2.1m for its freehold properties, and a further amount for its fixtures and fittings, motor vehicles and stock. An FRP spokesperson told The Standard that Medipharmacy, which operated a chain of 25 NHS community pharmacies across London, Kent, Surrey and West Sussex, had faced increasing cashflow challenges in recent months. According to the administrators' report, Medipharmacy's revenues had grown exponentially from £27.9m in 2022 to £69m in 2023 but didn't deliver corresponding improvements in profitability.

The Pharmacists' Defence Association (PDA) has submitted evidence to the NHS Pay Review Body (PRB), emphasising on the recruitment and retention of NHS pharmacists. It has urged the PRB to help the NHS achieve two important objectives - ensuring that pharmacists can achieve well-rewarded and the service is viewed as an a ppealing alternative by student pharmacists. The PDA suggested that for the NHS to remain competitive, the PRB should focus its pay approach on employees within Bands 5-8 this year. It recognised that the last recommendation from the PRB was a "flat rate increase" and it left those working in the above-mentioned bands feeling "unhappy", which led to the CSP taking strike action over pay for the first time in their history.

The Department of Health and Social Care (DHSC) has redetermined the December 2023 concessionary prices for four medicines following requests made by Community Pharmacy England (CPE) on behalf of community pharmacy owners. For Ezetimibe 10mg tablets (pack size 28), the price has been fixed at £17.78, up from £9.44. Other drugs included in the list are Aripiprazole 5mg (£8.52), Digoxin 125microgram (£3.70) and Digoxin 250micrgram (£3.70) tablets. Contractors would be reimbursed at the new prices only for prescriptions submitted for payment for the dispensing month of December 2023. CPE said they are still working with DHSC to agree price concessions for January. Check the final the December 2023 price concessionary here. Additionally, DHSC on Friday confirmed that there's now sufficient stock of Clarithromycin 125mg/5ml oral suspension to meet normal demand, and the Serious Shortage Protocol (SSP), SSP053 for the antibiotic expires on 12 January 2024.

Campaigners have submitted an open letter to the Department of Health and Social Care (DHSC), urging the Minister for Primary Care and Public Health to freeze prescription charges to keep people with long-term conditions alive and well. The campaign is led by the Prescription Charges Coalition, which represents over 50 organisations, including Royal Pharmaceutical Society (RPS) and Pharmacists' Defence Association (PDA). Currently, the prescription charge is £9.65 per item, and campaigners have asked the government to freeze it for 2024 and 2025 as people living with long-term health conditions in England are "being forced to choose between heating, eating, and taking their vital medication on a daily basis." In 2023, a study conducted by the Prescription Charges Coalition revealed that almost 10 per cent of survey participants had skipped medication in the previous year due to the cost of prescriptions. This led to increased physical and mental health problems, as well as impacted the time they took off work. Laura Cockram, Chair of the Prescription Charges Coalition and Head of Campaigns at Parkinson's UK, expressed deep concern that a further rise in the charge this year will lead to people skipping or not taking the full dose of their medication, which will affect their health and put more pressure on the already under pressure NHS.

In a recent announcement, the British supermarket chain, Asda has launched its first online prescription service becoming the first self-serving shop to offer prescribed medicine supply at the doorsteps through its latest healthcare accessibility venture. The NHS certified online pharmacy service, Asda Online Pharmacy, is set to offer patients a digital platform designed to simplify the prescription process for patients, offering the convenience of online management and home delivery with their partnership with Pharmacy2U. Effective immediately, new patients can register for an account on the platform via pharmacy.asda.com. Once registered, they gain access to a seamless prescription ordering system that facilitates home delivery, along with the ability to monitor the progress of their orders. Prescriptions submitted through Asda Online Pharmacy will undergo rigorous scrutiny by qualified pharmacists before being dispatched directly to patients' doorsteps, all without any additional charges.

PBR Staff Writer Published 21 February 2014 Israel-based Pluristem Therapeutics has submitted its application to the US Food and Drug Administration seeking Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells for the treatment of severe preeclampsia.

US-based KYTHERA Biopharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for ATX-101 (deoxycholic acid) as an injectable treatment for the reduction of submental fat, which commonly presents as a double chin.

We are dealing with a public health emergency, and CMS has proactively come forward to facilitate clinicians in Quality Payment Program (QPP). This year, the final rule for QPP MIPS data submission required some flexibility to accommodate the pressure.

CMS (Centers for Medicare and Medicaid Services) launched an alternative payment model - Primary Car. In this program, eligible clinicians can submit quality measures including for Advance Care Plan at the end of the performance year.

Up, close, and personal with MIPS Quality reporting. We have some of the measures if not all for the 2020 performance year. Providers, kindly, take a look at them and also give us your feedback.

Up, close, and personal with MIPS Quality reporting. We have some of the measures if not all for the 2020 performance year. Providers, kindly, take a look at them and also give us your feedback.

Up, close, and personal with MIPS Quality reporting. We have some of the measures if not all for the 2020 performance year. Providers, kindly, take a look at them and also give us your feedback.

Quality payment program has significantly influence medical billing services in the USA. They have achieved milestones in this field. This field is quite tough as it requires great focus and attention for creating and submitting accurate medical claims so that, healthcare providers are rightfully reimbursed for their rendered services.

We found that the MIPS 2020 and MIPS 2019 Quality measures are more similar than they are different. Nevertheless, we got into a bit of detail in this article to give you a better idea.

In MIPS 2019 and MIPS 2020, participants get to submit 6 quality measures data for 12 months (from January 1 to December 31, 2019, and January 1 to December 31, 2020, respectively). The amount of data to undergo submission depends on the collection (measure) type.

Here is a MIPS 2020 reporting checklist to ensure we are right on track and submit data right on time.

The window for MIPS 2019 performance score review is closed now. Now, eligible physicians must focus on MIPS 2020 data submission and enjoy flexibilities amidst COVID to compensate for the lost revenue.

Join us for the prestigious Pharmacy Business Awards 2023, celebrating excellence in community pharmacy. Attend the glittering ceremony in London and witness industry leaders, officials, and ministers. Submit your entry now and showcase the unique services of community pharmacy. Nomination deadline: July 7th, 2023.

Representatives from the National Pharmacy Association (NPA) and the Royal Pharmaceutical Society (RPS) presented their preliminary evidence to the Inquiry, which is examining the impact of the COVID-19 pandemic on healthcare systems in the UK. The UK COVID-19 Inquiry began on 28 June 2022 to examine the UK's preparedness and response to the pandemic, aiming to draw insights for the future. Its investigations are organised into modules, gathering evidence from witnesses, experts and core participants through a series of corresponding hearings throughout each module. A preliminary Module 3 hearing for its investigation into was held at Dorland House, 121 Westbourne Terrace, London, W2 6BU on Wednesday 10 April at 10.30am. NPA calls for funding to boost pharmacy resilience Presenting its evidence before the inquiry, the NPA highlighted the unsung contribution of pharmacies nationwide in combatting COVID-19 and maintaining health services throughout the pandemic while calling for funding to create greater resilience in community pharmacies.